August 16, 2019

Participants ages 18-65 with primary FSGS needed for phase 2 adaptive study

The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics of PF006730512 following multiple intravenous infusion in adult subjects with primary FSGS. You may qualify if you are a male or female ages 18 - 65, with an eGFR >45, a UPCR >1.5 g/g, also a non-Responder to a Single Treatment regimen for FSGS, considered intolerant to an Immunosuppressant and are a Non-Responder to a single treatment regimen, or considered intolerant to an Immunosuppressant and are naïve to other Immunosuppressant treatment regimens for FSGS. Must discontinue steroid treatment or tapered down to a stable prednisone dose 7.5 mg per day or other steroid equivalents to achieve a stable dose before the Lead-In Period. Participants must be willing and able to comply with scheduled visits, must comply with birth control regimen or have proof of postmenopausal status. If you are interested please contact Teresa Chacana at (205) 934-7649